FDA Approves First Targeted Therapy for HER2-Low Breast Cancer Dr. Kamal Kant Kohli6 Aug 2022 8:00 AM ISTThe U.S. Food and Drug Administration has approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV infusion for the treatment of patients with...
MRI guided high-intensity focused ultrasound can control prostate cancer with fewer side effects: Lancet Dr. Kamal Kant Kohli26 Jun 2022 8:00 PM ISTIn recent years, a new treatment strategy known as focal therapy (partial gland ablation) has emerged for prostate cancer considered to be...
USFDA nod to Novartis Tafinlar plus Mekinist for solid tumors with gene mutation Ruchika Sharma23 Jun 2022 2:47 PM ISTBRAF V600E is the most common type of BRAF mutation, accounting for up to 90% of BRAF-mutant cancers.
Probiotic bacteria may enhance tamoxifen effectiveness in treatment of ER+ breast cancer Dr. Kamal Kant Kohli22 Jun 2022 7:45 PM ISTProbiotic bacteria may enhance anti-cancer activities of the breast cancer drug tamoxifen and other endocrine-targeted therapies, which could help...
First Mutation-Targeted Bladder Cancer Drug May Be Under-Used Dr. Kamal Kant Kohli19 May 2022 8:00 PM IST PHILADELPHIA: The first bladder cancer drug targeting a cancer-driving gene mutation has been used relatively little despite its clear efficacy...
New CAR T-cell therapy for solid tumors was safe and showed early efficacy Dr. Kamal Kant Kohli29 April 2022 9:00 AM ISTNEW ORLEANS: A new chimeric antigen receptor (CAR) T-cell product had an acceptable safety profile and showed early signs of efficacy as a monotherapy...
Nintedanib found effective for drug resistant gastrointestinal stromal tumors Dr. Kamal Kant Kohli15 April 2022 7:30 PM ISTNintedanib could be used in the treatment of drug-resistant gastrointestinal stromal tumors (GISTs), finds a research led by Prof. LIU Qingsong and...
FDA approves first topical treatment for facial angiofibroma associated with tuberous sclerosis Dr. Kamal Kant Kohli5 April 2022 9:30 AM ISTBETHESDA- The Food and Drug Administration has approved sirolimus 0.2% gel (Hyftor) as the first topical treatment for facial angiofibroma associated...
Minimally Invasive Hysterectomy has Poorer Disease-Free Survival Than Open Surgery in Cervical Cancer Dr. Kamal Kant Kohli4 April 2022 9:00 AM ISTPHOENIX: Minimally invasive surgery was associated with lower survival rates than open surgery as a treatment for cervical cancer, according to the...
Adrenalectomy during radical nephrectomy may not improve survival in renal cell carcinoma: Study Dr. Shravani Dali24 Jun 2021 5:27 PM ISTAdrenalectomy conducted during radical nephrectomy has no significant benefit in improving the survival outcome in patients of renal cell carcinoma,...
Successful outcome of a nephron-sparing surgery in a solitary kidney with multiple renal masses Saurabh Ramesh Patil24 Feb 2021 1:21 PM ISTSurgical excision offers the best chance of cancer control in cases of kidney cancers. This can be achieved either by total removal, also known as...
Study demonstrates efficacy of new treatment for neurofibromatosis type 1-related tumors Hina Zahid24 Jan 2021 10:39 PM ISTPhiladelphia: Based on preclinical studies of an investigational drug to treat peripheral nerve tumors, researchers at Children's Hospital of...
